摘要
神经调节蛋白-1(NRG1)是一个公认的精神分裂症的风险基因,并且经常与这种疾病的神经发育假说相关。NRG1基因的可变剪接和蛋白酶解加工产生超过30种结构变异体;然而,个别变异的神经病理作用仍有待表征。根据精神分裂症的神经发育假说,我们用eNRG1(0.1~1.0 μg/g),常见的所有剪接NRG1变体中一个核心表皮生长因子(EGF),比较了新生小鼠和一个挑战1型NRG1变体的完整成熟小鼠的行为表现。在新生儿阶段,使用重组eNRG1蛋白从外周通过血- 脑屏障和激活脑中的受体(ErbB4)。在成年老鼠中,接受最高剂量的老鼠表现出最低的运动活性和前脉冲抑制不足及音调依耐性恐惧学习,尽管eNRG1治疗老鼠听力降低可以解释这些行为不足。新生儿eNRG1治疗可显著加强MK – 801驱使的运动活性,且以一种eNRG1剂量依赖的方式。在成年老鼠大脑中,平行的eNRG1治疗能够增强MK-801驱使的c-Fos感应和减少对于NMDA受体亚基的免疫反应性。相反,用相同摩尔剂量的完整成熟形式1型NRG1,新生儿未显示出对MK-801过敏。然而,动物模型对甲基苯丙胺表现出类似的过敏症状。总之,我们的研究结果表明,异常的外围NRG1信号在神经发育过程中改变后的行为特征和听觉功能呈NRG1亚型依赖性。
关键词: 行为,MK-801,神经调节蛋白,NMDA受体,听力,神经分裂症
Current Molecular Medicine
Title:Neurobehavioral Differences Between Mice Receiving Distinct Neuregulin Variants as Neonates; Impact on Sensitivity to MK-801
Volume: 15 Issue: 3
Author(s): T. Kato, Y. Abe, S. Hirokawa, Y. Iwakura, M. Mizuno, H. Namba and H. Nawa
Affiliation:
关键词: 行为,MK-801,神经调节蛋白,NMDA受体,听力,神经分裂症
摘要: Neuregulin-1 (NRG1) is a well-recognized risk gene for schizophrenia and is often implicated in the neurodevelopmental hypothesis of this illness. Alternative splicing and proteolytic processing of the NRG1 gene produce more than 30 structural variants; however, the neuropathological roles of individual variants remain to be characterized. On the basis of the neurodevelopmental hypothesis of schizophrenia, we administered eNRG1 (0.1~1.0 μg/g), a core epidermal growth factor-like (EGF) domain common for all splicing NRG1 variants, to neonatal mice and compared their behavioral performance with mice challenged with a full mature form of type 1 NRG1 variant. During the neonatal stage, recombinant eNRG1 protein administrated from the periphery passed the blood-brain barrier and activated its receptor (ErbB4) in the brain. In adults, the mice receiving the highest dose exhibited lower locomotor activity and deficits in prepulse inhibition and tonedependent fear learning, although the hearing reduction of the eNRG1-treated mice may explain these behavioral deficits. Neonatal eNRG1 treatment also significantly potentiated MK-801-driven locomotor activity in an eNRG1 dose-dependent manner. In parallel eNRG1 treatment enhanced MK-801-driven c-Fos induction and decreased immunoreactivity for NMDA receptor subunits in adult brain. In contrast, mice that had been treated with the same molar dose of a full mature form of type 1 NRG1 as neonates did not exhibit hypersensitivity to MK-801. However, both animal models exhibited similar hypersensitivity to methamphetamine. Collectively, our findings suggest that aberrant peripheral NRG1 signals during neurodevelopment alter later behavioral traits and auditory functions in the NRG1 subtype-dependent manner.
Export Options
About this article
Cite this article as:
T. Kato, Y. Abe, S. Hirokawa, Y. Iwakura, M. Mizuno, H. Namba and H. Nawa , Neurobehavioral Differences Between Mice Receiving Distinct Neuregulin Variants as Neonates; Impact on Sensitivity to MK-801, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330143300
DOI https://dx.doi.org/10.2174/1566524015666150330143300 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Non-Contact Electrodes for Measuring EEG and EKG
Recent Patents on Electrical & Electronic Engineering Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry Experimental Treatment Options in Absence Epilepsy
Current Pharmaceutical Design Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Treatment of Hypertension Induced Target Organ Damage in Children and Adolescents
Current Pharmaceutical Design Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Default Mode, Executive Function, and Language Functional Connectivity Networks are Compromised in Mild Alzheimer´s Disease
Current Alzheimer Research Neuroimaging in Obsessive-Compulsive Disorder
Current Medical Imaging Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets CGRP Receptor Antagonists: Toward a Novel Migraine Therapy
Current Pharmaceutical Biotechnology PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Disorders of Sex Development: A Review
Current Women`s Health Reviews M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Current Alzheimer Research STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery